On March 3, 2022 Herantis Pharma Plc ("Herantis"), developing disease modifying therapies for Parkinson’s disease, reported the company’s Year-end report for 2021 (Press release, Herantis Pharma, MAR 3, 2022, View Source,c3517887 [SID1234609424]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
A live webinar (in English) will be held today, at 10:00 EET / 9:00 CET.
Link to Registration: Herantis’ FY 2021 Report Webinar
Highlights January-December 2021
Significant progress has been made with HER-096:
Selection of HER-096 as the lead candidate for development based on efficacy, safety, pharmacokinetic, pharmacodynamic and stability criteria.
Demonstration of HER-096 penetrating the blood brain barrier and entering the brain in therapeutic concentrations after a single subcutaneous administration in a rat model.
Confirmation of a unique mechanism of action, similar to CDNF, resulting in a significant reduction of alpha-synuclein deposition, neuroinflammation, and remarkable restoration of dopaminergic neurons in preclinical disease models
Identification of novel biomarker candidates in the Phase 1b Cerebral Dopamine Neurotrophic Factor (CDNF) study aimed at supporting future clinical development of HER-096
Other operational highlights:
A collaboration with Nanoform Finland Plc. was formed to investigate the feasibility of applying the nanoforming process to rhCDNF. In 2021, we established that nanoformed rhCDNF nanoparticles retain their stability and activity.
Formation of Herantis Scientific Advisory Board (SAB), consisting of leading experts in the development of therapies for Parkinson’s disease from industry and academia: Dr.Anders Gersel Pedersen M.D. (chair), Dr. Daniele Bravi M.D., Prof. David Dexter, PhD, and Prof. Alberto Espay M.D. MSc
Hilde Furberg, MSc, an experienced biopharma executive, was elected to the Board of Directors
Completion of a private placement exceeding EUR 4.0 million
Herantis published several papers and scientific posters in scientific media and conferences during 2021
Events after year end 2021
On January 20th, 2022, Herantis Pharma’s Board of Directors appointed Frans Wuite, MD, MBA, as the interim CEO, effective immediately. Wuite is also the Vice Chairman of Herantis’ Board of Directors and will continue in this role. Herantis’ CEO until January 20th, 2022, Dr. Craig Cook, left the company following the Board of Directors’ decision. A search for a permanent CEO will be launched. In connection with the CEO transition and following strong preclinical data in 2021, Herantis’ Board of Directors has decided to focus a significant majority of the company’s development efforts to advance HER-096, a small, synthetic peptidomimetic molecule derived from the active site of CDNF. HER-096 combines the unique mode of action of the CDNF protein to target Parkinson’s disease with the ease of subcutaneous administration.
Group’s Key Figures:
Year-end 2021 Report Webinar Details
Interim CEO, Frans Wuite, MD will present Herantis and comment on the Year-end 2021 report followed by a live Q&A session. Please join the webinar a few minutes in advance.